Based on the key indicators related to Mink Therapeutics' liquidity, profitability, solvency, and operating efficiency, Mink Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March. At this time, Mink Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Total is likely to gain to about 15.7 M in 2025, whereas Total Stockholder Equity is likely to drop (21.8 M) in 2025. Key indicators impacting Mink Therapeutics' financial strength include:
The financial analysis of Mink Therapeutics is a critical element in measuring its lifeblood. Investors should not minimize Mink Therapeutics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
(21.22 Million)
Mink
Select Account or Indicator
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Capex Per Share
Graham Net Net
Interest Debt Per Share
Enterprise Value Over E B I T D A
Price Earnings Ratio
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Return On Capital Employed
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Free Cash Flow Operating Cash Flow Ratio
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Return On Assets
Price Fair Value
Return On Equity
Investments
Change In Cash
Net Borrowings
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Sale Purchase Of Stock
Total Assets
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Net Tangible Assets
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Cash And Short Term Investments
Net Receivables
Common Stock Shares Outstanding
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Net Invested Capital
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Capital Stock
Non Current Liabilities Other
Net Working Capital
Common Stock
Property Plant Equipment
Net Interest Income
Depreciation And Amortization
Interest Expense
Selling General Administrative
Gross Profit
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Cost Of Revenue
Probability Of Bankruptcy
Understanding current and past Mink Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Mink Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Mink Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Mink Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Mink Therapeutics. Check Mink Therapeutics' Beneish M Score to see the likelihood of Mink Therapeutics' management manipulating its earnings.
Mink Therapeutics Stock Summary
Mink Therapeutics competes with Affimed NV, Adaptimmune Therapeutics, Sangamo Therapeutics, Day One, and Acumen Pharmaceuticals. MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc. Mink Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 33 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
The reason investors look at the income statement is to determine what Mink Therapeutics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
Comparative valuation techniques use various fundamental indicators to help in determining Mink Therapeutics's current stock value. Our valuation model uses many indicators to compare Mink Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mink Therapeutics competition to find correlations between indicators driving Mink Therapeutics's intrinsic value. More Info.
Mink Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Mink Therapeutics' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Mink Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Mink Therapeutics Systematic Risk
Mink Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Mink Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Mink Therapeutics correlated with the market. If Beta is less than 0 Mink Therapeutics generally moves in the opposite direction as compared to the market. If Mink Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Mink Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Mink Therapeutics is generally in the same direction as the market. If Beta > 1 Mink Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Mink Therapeutics Thematic Clasifications
Mink Therapeutics is part of Biotech investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services
This theme covers Biotechnology and pharmaceuticals production and services. Companies specialized in biotechnology production and delivery of pharmaceuticals services. Get More Thematic Ideas
Today, most investors in Mink Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Mink Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Mink Therapeutics growth as a starting point in their analysis.
Mink Therapeutics February 16, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Mink Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Mink Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Mink Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Mink Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Mink Therapeutics's daily price indicators and compare them against related drivers.
When running Mink Therapeutics' price analysis, check to measure Mink Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mink Therapeutics is operating at the current time. Most of Mink Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mink Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mink Therapeutics' price. Additionally, you may evaluate how the addition of Mink Therapeutics to your portfolios can decrease your overall portfolio volatility.